Similarly, approaches using hypoxia-responsive promoters combined with the cytotoxic protein BAX after viral delivery or hypoxia-dependent E1A expression for hypoxia-targeted virus replication are promising candidates for cancer therapy [39]. This evidence concerns the gene DHTKD1 and cancer.